CU24699B1 - Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b - Google Patents

Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b

Info

Publication number
CU24699B1
CU24699B1 CU2020000009A CU20200009A CU24699B1 CU 24699 B1 CU24699 B1 CU 24699B1 CU 2020000009 A CU2020000009 A CU 2020000009A CU 20200009 A CU20200009 A CU 20200009A CU 24699 B1 CU24699 B1 CU 24699B1
Authority
CU
Cuba
Prior art keywords
hepatitis
virus
compositions
treat
prevent infection
Prior art date
Application number
CU2020000009A
Other languages
English (en)
Other versions
CU20200009A7 (es
Inventor
Yi Zhang
Original Assignee
Yisheng Biopharma Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yisheng Biopharma Singapore Pte Ltd filed Critical Yisheng Biopharma Singapore Pte Ltd
Publication of CU20200009A7 publication Critical patent/CU20200009A7/es
Publication of CU24699B1 publication Critical patent/CU24699B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>Esta invención se refiere a composiciones para tratar y/o prevenir Ia infección por el virus de Ia hepatitis B y las enfermedades mediadas por Ia infección por el virus de Ia hepatitis B. En algunas modalidades, Ia composición incluye un ácido polirriboinosínico-ácido poliribocitidílico (PIC), un compuesto antibiótico o de poliamida, un ion positivo y un antígeno de superficie del virus de Ia hepatitis B. En algunas modalidades, Ia composición incluye PIC, un compuesto antibiótico o de poliamida, un ion positivo, antígeno de superficie del virus de Ia hepatitis B y antígeno central del virus de Ia hepatitis B.</p>
CU2020000009A 2017-08-10 2018-08-01 Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b CU24699B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201706540X 2017-08-10
PCT/SG2018/050391 WO2019032046A1 (en) 2017-08-10 2018-08-01 COMPOSITION FOR TREATING AND / OR PREVENTING HEPATITIS B VIRUS INFECTION AND USE THEREOF

Publications (2)

Publication Number Publication Date
CU20200009A7 CU20200009A7 (es) 2020-11-30
CU24699B1 true CU24699B1 (es) 2024-03-05

Family

ID=63524350

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000009A CU24699B1 (es) 2017-08-10 2018-08-01 Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b

Country Status (15)

Country Link
US (2) US11135286B2 (es)
EP (1) EP3664840B1 (es)
KR (1) KR20200047524A (es)
CN (1) CN110944662A (es)
AU (1) AU2018313636B2 (es)
BR (1) BR112020002627A2 (es)
CA (1) CA3070935A1 (es)
CU (1) CU24699B1 (es)
MX (1) MX2020001226A (es)
MY (1) MY202256A (es)
PH (1) PH12020500176A1 (es)
RU (1) RU2020108205A (es)
SG (1) SG11202000347UA (es)
WO (1) WO2019032046A1 (es)
ZA (1) ZA202001413B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021278137A1 (en) * 2020-05-29 2023-01-05 Beijing Yisheng Biotechnology Co., Ltd. Pharmaceutical composition comprising polynucleotides and use thereof for prevention or treatment of COVID-19
CN111529516B (zh) * 2020-06-04 2022-03-15 山东大学 亚精胺在制备抗乙型肝炎病毒药物方面的应用
LT4243797T (lt) 2020-11-16 2026-06-10 Orcosa Inc. Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN122163588B (zh) * 2026-05-13 2026-08-11 广州医科大学附属妇女儿童医疗中心 精胺在制备治疗胆道闭锁药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
KR101203401B1 (ko) * 2005-06-08 2012-11-22 이쉥 바이오파마(싱가포르)피티이 리미티드 폴리이노신산-폴리시티딜산-기초 보조제
CN101501055B (zh) * 2005-06-23 2016-05-11 贝勒医学院 负性免疫调节因子的调节和免疫疗法应用
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
US20090136538A1 (en) 2006-05-22 2009-05-28 Jan Jezek Stable vaccine formulation
KR101329374B1 (ko) * 2008-12-09 2013-11-14 콜레이 파마시티컬 그룹, 인코포레이티드 면역자극성 올리고뉴클레오타이드
US9480714B2 (en) 2012-11-13 2016-11-01 Allan Yang Wu Methods and systems for processing exosomes
CN110305133A (zh) * 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
SI3507276T1 (sl) * 2016-09-02 2022-01-31 Gilead Sciences, Inc. Spojine modulatorja toličnih receptorjev
KR20190093816A (ko) * 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
US11324820B2 (en) * 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection

Also Published As

Publication number Publication date
US20220211840A1 (en) 2022-07-07
CA3070935A1 (en) 2019-02-14
US11135286B2 (en) 2021-10-05
EP3664840A1 (en) 2020-06-17
RU2020108205A3 (es) 2022-01-31
MX2020001226A (es) 2020-07-20
WO2019032046A1 (en) 2019-02-14
BR112020002627A2 (pt) 2020-07-28
AU2018313636B2 (en) 2024-10-17
SG11202000347UA (en) 2020-02-27
RU2020108205A (ru) 2021-09-10
US20200222529A1 (en) 2020-07-16
US11690909B2 (en) 2023-07-04
PH12020500176A1 (en) 2020-09-14
CU20200009A7 (es) 2020-11-30
ZA202001413B (en) 2024-12-18
EP3664840B1 (en) 2026-07-08
AU2018313636A1 (en) 2020-03-26
CN110944662A (zh) 2020-03-31
MY202256A (en) 2024-04-19
KR20200047524A (ko) 2020-05-07

Similar Documents

Publication Publication Date Title
CU20200009A7 (es) Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b
CL2020001146A1 (es) Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
CO2019001379A2 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih .
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
BR112017011941A2 (pt) compostos 5-amino-6h-tiazol [4,5-d] pirimidina-2,7-diona substituídos 3 para o tratamento e profilaxia de infecção viral
CL2020001145A1 (es) Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb).
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
MX2023013140A (es) Vacunas contra el virus de la hepatitis b.
EA201890494A1 (ru) Способы лечения вирусных инфекций arenaviridae и coronaviridae
MX346264B (es) Compuestos antivirales.
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
PE20191461A1 (es) Compuestos amida para el tratamiento del vih
CL2020001147A1 (es) Compuestos antibacterianos
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
MX389999B (es) Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral
CO2021012583A2 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
BR112017003663A2 (pt) composto, composição, e, método para tratamento de infecção por hiv.
CU20210061A7 (es) Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer
GB2544439A (en) Antiviral composition
AR106057A1 (es) Composición con efecto antiviral, composición farmacéutica
BR112017009501A2 (pt) método para tratar uma infecção por hcv, método para curar uma infecção por hcv, e, composição farmacêutica.